Translational Medical Oncology Unit (OMT)

Director Prof. Pierfrancesco Tassone, MD

OMT is a medical oncology clinical unit specifically devoted to the treatment of solid and haematological human malignancies, with special focus to the design of translational clinical trials for innovative drugs both in the early (Early Clinical Trials – Phase I) and in more advanced phases (Phase II and III).

Moreover the OMT is a clinical and technological node of the Calabrian Re.Ca.Tur. (Calabrian Network for Rare Tumors) devoted to the biological and molecular typing of rare tumors and treatment personalisation based on innovative technologies. In this context specific interest is focused on the study of multiple myeloma and BRCA-defective breast and ovarian cancer or other hereditary cancer syndromes.